Evidence map›Paper›PMID 38498285›Full record

ArticleEJNMMI research2024

Kevin Wyszatko, Melissa Chassé, Nancy Janzen, Luis Rafael Silva, Luke Kwon, Teesha Komal, Manuela Ventura, Chitra Venugopal, Sheila K Singh, John F Valliant and 1 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Molecular Imaging of Cancer Stem Cells and Their Role in Therapy Resistance.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Kevin WyszatkoDepartment of Chemistry and Chemical Biology, McMaster University, Hamilton, ON, Canada.
Melissa ChasséInstitute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Nancy JanzenDepartment of Chemistry and Chemical Biology, McMaster University, Hamilton, ON, Canada.
Luis Rafael SilvaDepartment of Chemistry and Chemical Biology, McMaster University, Hamilton, ON, Canada.
Luke KwonSpatio-Temporal Targeting and Amplification of Radiation Response Innovation Centre (STTARR), University Health Network, Toronto, ON, Canada.
Teesha KomalSpatio-Temporal Targeting and Amplification of Radiation Response Innovation Centre (STTARR), University Health Network, Toronto, ON, Canada.
Manuela VenturaSpatio-Temporal Targeting and Amplification of Radiation Response Innovation Centre (STTARR), University Health Network, Toronto, ON, Canada.
Chitra VenugopalCentre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada.
Sheila K SinghCentre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada.
John F ValliantDepartment of Chemistry and Chemical Biology, McMaster University, Hamilton, ON, Canada.
Saman SadeghiDepartment of Chemistry and Chemical Biology, McMaster University, Hamilton, ON, Canada. sadegs10@mcmaster.ca.ORCID http://orcid.org/0000-0002-2158-2703
McMaster University · CAUniversity Health Network · CADiscovery Centre · CAUniversity of Toronto · CA

Funding

Canadian Institute of Health Research 201903PJT-421287Natural Sciences and Engineering Research Council of Canada RGPIN-2022-05201Ontario Institute for Cancer Research
6 · The paper itself

Abstract

backgroundCancer stem cells play an important role in driving tumor growth and treatment resistance, which makes them a promising therapeutic target to prevent cancer recurrence. Emerging cancer stem cell-targeted therapies would benefit from companion diagnostic imaging probes to aid in patient selection and monitoring response to therapy. To this end, zirconium-89-radiolabeled immunoPET probes that target the cancer stem cell-antigen CD133 were developed using fully human antibody and antibody scFv-Fc scaffolds.

resultsImmunoPET probes [

conclusionsFully human CD133-targeted immunoPET probes [

Indexed as

AntibodyAntibody fragmentCancer Stem cellsCD133ImmunoPETZirconium-89

Identifiers

PMID38498285
PMCPMC10948676
OpenAlexW4392910246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.